Square Pharmaceuticals is forecast to grow earnings and revenue by 11.4% and 10.1% per annum respectively. EPS is expected to grow by 11.4% per annum. Return on equity is forecast to be 18.2% in 3 years.
Key information
11.4%
Earnings growth rate
11.40%
EPS growth rate
Pharmaceuticals earnings growth
16.2%
Revenue growth rate
10.1%
Future return on equity
18.23%
Analyst coverage
Low
Last updated
27 Apr 2026
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
DSE:SQURPHARMA - Analysts future estimates and past financials data (BDT Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
6/30/2029
115,908
37,810
26,672
36,470
3
6/30/2028
105,008
33,792
24,405
33,568
3
6/30/2027
95,263
30,691
22,504
30,015
3
6/30/2026
85,112
26,600
16,949
24,256
3
3/31/2026
83,527
25,863
13,979
22,300
N/A
12/31/2025
81,952
25,948
15,032
21,629
N/A
9/30/2025
80,128
25,280
14,555
20,543
N/A
6/30/2025
76,288
23,968
11,125
17,302
N/A
3/31/2025
75,860
23,503
8,193
13,723
N/A
12/31/2024
72,266
22,375
6,330
13,124
N/A
9/30/2024
70,037
21,017
8,105
13,518
N/A
6/30/2024
70,101
20,926
14,348
18,529
N/A
3/31/2024
64,651
20,238
10,303
14,192
N/A
12/31/2023
64,004
19,599
12,052
13,911
N/A
9/30/2023
64,489
19,480
9,620
11,800
N/A
6/30/2023
60,708
18,980
5,685
8,546
N/A
3/31/2023
62,020
18,856
6,968
10,289
N/A
12/31/2022
60,782
19,143
6,252
10,594
N/A
9/30/2022
58,791
18,680
6,859
12,222
N/A
6/30/2022
57,598
18,157
6,692
12,875
N/A
3/31/2022
56,713
18,526
8,514
14,936
N/A
12/31/2021
54,834
17,819
8,307
14,183
N/A
9/30/2021
53,004
17,012
9,070
13,949
N/A
6/30/2021
50,703
15,947
7,178
10,976
N/A
3/31/2021
49,021
14,484
7,344
10,544
N/A
12/31/2020
48,395
14,237
9,532
12,249
N/A
9/30/2020
47,158
13,933
7,903
10,427
N/A
6/30/2020
45,876
13,354
8,718
10,760
N/A
3/31/2020
46,360
13,733
10,203
12,019
N/A
12/31/2019
45,138
13,236
N/A
11,586
N/A
9/30/2019
44,785
12,831
N/A
12,455
N/A
6/30/2019
44,034
12,646
N/A
12,392
N/A
3/31/2019
42,322
12,168
N/A
10,525
N/A
12/31/2018
41,252
12,025
N/A
9,288
N/A
9/30/2018
40,328
11,754
N/A
9,493
N/A
6/30/2018
39,654
11,594
N/A
9,905
N/A
3/31/2018
39,474
11,667
N/A
9,371
N/A
12/31/2017
39,131
11,622
N/A
10,071
N/A
9/30/2017
37,978
11,222
N/A
9,723
N/A
6/30/2017
36,543
10,637
N/A
9,542
N/A
3/31/2017
35,584
10,330
N/A
9,806
N/A
12/31/2016
34,534
9,893
N/A
9,348
N/A
9/30/2016
33,448
9,639
N/A
10,637
N/A
6/30/2016
33,074
9,199
N/A
9,615
N/A
12/31/2015
29,642
7,770
N/A
9,487
N/A
9/30/2015
28,400
7,091
N/A
8,298
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SQURPHARMA's forecast earnings growth (11.4% per year) is above the savings rate (4.2%).
Earnings vs Market: SQURPHARMA's earnings (11.4% per year) are forecast to grow slower than the BD market (15% per year).
High Growth Earnings: SQURPHARMA's earnings are forecast to grow, but not significantly.
Revenue vs Market: SQURPHARMA's revenue (10.1% per year) is forecast to grow slower than the BD market (10.8% per year).
High Growth Revenue: SQURPHARMA's revenue (10.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SQURPHARMA's Return on Equity is forecast to be low in 3 years time (18.2%).
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/05 22:49
End of Day Share Price
2026/07/05 00:00
Earnings
2026/03/31
Annual Earnings
2025/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Square Pharmaceuticals PLC. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.